直接抗病毒药物治疗后持续病毒学应答对晚期肝病患者死亡率的影响
本研究纳入15059例FIB-4>3.25的丙型肝炎病毒感染晚期肝病患者,评估直接抗病毒药物诱导的持续病毒学应答(SVR)对全因死亡和肝癌发生的影响。平均随访约1.6年,SVR组死亡率较无SVR组降低78.9%(P<0.001),肝癌发生率降低83.5%(P<0.001)。结论:获得SVR者全因死亡率和肝癌发生率均显著低于未获得SVR者。
要点
- 在FIB-4>3.25的晚期肝病患者中,直接抗病毒治疗后获得SVR与全因死亡率降低78.9%相关(P<0.001)。
- 获得SVR者肝癌发生率较未获得SVR者降低83.5%(P<0.001)。
- 多变量Cox模型显示SVR与死亡风险降低独立相关(HR 0.26,95%CI 0.22-0.31,P<0.001)。
核心结论
- 直接抗病毒治疗后获得SVR的患者全因死亡率和肝癌发生率均显著低于未获得SVR者。
研究设计与样本
- 本研究纳入15059例丙型肝炎病毒感染且FIB-4>3.25的晚期肝病患者,其中1067例未获得SVR,13992例获得SVR,平均随访约1.6年。
主要发现
- 随访期间无SVR组195例死亡,SVR组598例死亡;死亡率分别为12.3例/100患者年 vs 2.6例/100患者年,降低78.9%(P<0.001)。
- 在既往无肝癌诊断的患者中,无SVR组140例、SVR组397例新发肝癌;肝癌发生率分别为11.5例/100患者年 vs 1.9例/100患者年,降低83.5%(P<0.001)。
- 多变量Cox比例风险模型显示,与无SVR相比,SVR与死亡风险降低独立相关(HR 0.26,95%CI 0.22-0.31,P<0.001)。
- 失代偿肝病史(HR 1.57,95%CI 1.34-1.83,P<0.001)和白蛋白每降低1 g/dL(HR 2.70,95%CI 2.38-3.12,P<0.001)与死亡风险增加独立相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The impact of sustained virologic response (SVR) on mortality after direct-acting antiviral treatment is not well documented. This study evaluated the impact of direct-acting antiviral-induced SVR on all-cause mortality and on incident hepatocellular carcinoma (HCC) in 15,059 hepatitis C virus-infected patients with advanced liver disease defined by a FIB-4 >3.25. Overall, 1,067 patients did not achieve SVR (no SVR) and 13,992 patients achieved SVR. In a mean follow-up period of approximately 1.6 years, 195 no SVR patients and 598 SVR patients died. Mortality rates were 12.3 deaths/100 patient years of follow-up for no SVR patients and 2.6 deaths/100 patient years for SVR patients, a 78.9% reduction (P < 0.001). Among patients without a prior diagnosis of HCC, 140 no SVR patients and 397 SVR patients were diagnosed with incident HCC. HCC rates were 11.5 HCCs/100 patient years for no SVR patients and 1.9 HCCs/100 patient years for SVR patients, an 83.5% reduction (P < 0.001). In multivariable Cox proportional hazard models controlling for baseline demographics, clinical characteristics, and comorbidities, SVR was independently associated with reduced risk of death compared to no SVR (hazard ratio, 0.26; 95% confidence interval, 0.22-0.31; P < 0.001). A history of decompensated liver disease (hazard ratio, 1.57; 95% confidence interval, 1.34-1.83; P < 0.001) and decreased albumin (hazard ratio, 2.70 per 1 g/dL decrease; 95% confidence interval, 2.38-3.12; P < 0.001) were independently associated with increased risk of death. Conclusion: Those achieving SVR after direct-acting antiviral treatment had significantly lower all-cause mortality and lower incident HCC rates than those who did not achieve SVR.
引用
- Backus LI, Belperio PS, Shahoumian TA, et al. Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease. Hepatology. 2018. PMID: 28749564. doi:10.1002/hep.29408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。